The Global Market for Parkinson’s Disease Drugs to 2024 – COMT (Catechol-O-Methyltransferase) Inhibitors to Register Robust Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Parkinson’s
Disease Drugs Market – Growth, Trends, and Forecast (2019-2024)”
report has been added to ResearchAndMarkets.com’s
offering.

Parkinson’s disease drugs market is expected to witness significant
growth, owing to the increasing cases of Parkinson’s disease, with the
growth in aging population levels. Therefore, it may drastically result
in increasing the market size during the forecast period.

Pharmaceutical firms are developing new and improved therapies for
Parkinson’s disease (PD), and recently, there have been some major
product launches in Parkinson disease therapeutics and other assistive
therapeutics.

For instance, Adamas Pharmaceuticals’ amantadine extended-release
capsules / Gocovri launched in Jan 2018, which was the first drug
indicated for dyskinesia developed due to long-term use of levodopa.

Furthermore, most of the global firms have a robust drug pipeline for
the treatment of Parkinson’s disease, and as per the estimates, the
forecast period may witness the launch of a few blockbuster drugs.

Key Market Trends

COMT (Catechol-O-Methyltransferase) Inhibitors are Expected to
Register Robust Growth

Carbidopa-levodopa Therapy is the most effective medication for
alleviating the motor symptoms of PD. However, it has been observed that
this medication is not as effective as intended. Therefore, it is
imperative that co-therapeutic agents, such as COMT
(catechol-O-methyltransferase) inhibitors, are used along with
carbidopa-levodopa therapy.

The two most common COMT inhibitors, used in the treatment of
Parkinson’s disease, are Comtan (entacapone) and Tasmar (tolcapone).
Both these medications are available in the form of tablets. In
addition, these medications are routinely prescribed in conjunction with
carbidopa-levodopa therapy.

The United States Represents the Largest Market for Parkinson’s
Disease Therapeutics

According to the National Institute of Health, approximately 1.2 million
people in the United States are predicted to have Parkinson’s disease by
2030. It is the second-most common neurodegenerative disorder in the
United States. In addition, there are thousands of patients who go
undetected. As the aging population levels continue to grow, the number
of people suffering from Parkinson’s disease (PD) will continue to grow,
and this is expected to double by 2040.

The sheer number of Parkinson’s disease patients, combined with the
availability of reimbursements and high awareness, is boosting the
growth of the market. Furthermore, the high cost of Parkinson’s disease
therapeutics in the United States also leads to significant market size
in terms of revenue. The average cost of Parkinson’s medication is
approximately USD 2,500 per year and Parkinson’s-related surgery can
cost up to USD 100,000 per patient.

Competitive Landscape

Parkinson’s disease drugs market is becoming highly competitive. The
recent product launches and the high number of therapeutics in product
pipelines of global pharmaceutical firms are contributing to the dynamic
nature of the market. Several new product launches are expected during
the forecast period, which may lead to significant changes in market
shares of pharmaceutical firms currently active in the market.

Key Topics Covered

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Geriatric Population

4.2.2 Recent Drug Approvals

4.2.3 Growing Awareness

4.3 Market Restraints

4.3.1 Generic Competition to Key Therapies

4.3.2 High Cost of Treatment

4.4 Porter’s Five Forces Analysis

5 MARKET SEGMENTATION

5.1 By Mechanism of Action

5.1.1 Dopamine Agonists

5.1.2 Anticholinergic

5.1.3 MAO-B inhibitors

5.1.4 Amantadine

5.1.5 Carbidopa-levodopa

5.1.6 COMT Inhibitors

5.1.7 Other Mechanisms of Action

5.2 Geography

5.2.1 North America

5.2.2 Europe

5.2.3 Asia-Pacific

5.2.4 Middle East & Africa

5.2.5 South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Merck & Co. Inc.

6.1.2 Impax Laboratories Inc.

6.1.3 AbbVie Inc.

6.1.4 Mylan N.V.

6.1.5 Boehringer Ingelheim

6.1.6 GlaxoSmithKline plc

6.1.7 M Somerset Pharmaceuticals Inc.

6.1.8 Teva Pharmaceuticals Industries Ltd.

6.1.9 Pfizer Inc.

6.1.10 Novartis AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/db4upx

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs